Recent advances in incretin-based therapies

Clinical Endocrinology

Volumn 77, Issue 4, 2012, Pages 489-499

  Russell Jones, David ^a   Gough, Stephen ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; ALBIGLUTIDE; ALOGLIPTIN; ANAGLIPTIN; ANTIDIABETIC AGENT; ARI 2243; BMS 686117; CARMEGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GOSOGLIPTIN; HEMOGLOBIN A1C; HM 11260C; INCRETIN; INSULIN; ITCA 650; KRP 104; LINAGLIPTIN; LIRAGLUTIDE; LY 2428757; LYXUMIA; MAR 701; MELOGLIPTIN; METFORMIN; NN 9924; PIOGLITAZONE; RO 0730699; RO 6807952; SAXAGLIPTIN; SITAGLIPTIN; SSR 162369; SULFONYLUREA DERIVATIVE; TA 6666; TENELIGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN; VRS 859; ZP 2929; ZP 3022;

CONTINUOUS INFUSION; DIABETES CONTROL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; VOMITING;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 84867304934     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04483.x     Document Type: Review

References (93)

1. Nauck, M., Stöckmann, F., Ebert, R. et al. (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia, 29, 46-52.
2. Baggio, L.L. & Drucker, D.J. (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology, 132, 2131-2157.
3. Holst, J.J. (2007) The physiology of glucagon-like peptide 1. Physiological Reviews, 87, 1409-1439.
4. Edholm, T., Degerblad, M., Grybäck, P. et al. (2010) Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterology & Motility, 22, 1191-1200, e315.
5. Vilsbøll, T. (2009) The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obesity and Metabolism 11(Suppl. 3), 11-18.
6. Nauck, M.A., Vardarli, I., Deacon, C.F. et al. (2011) Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia, 54, 10-18.
7. Nauck, M.A., Kleine, N., Orskov, C. et al. (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 36, 741-744.
8. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B. et al. (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577-1596.
9. Dirksen, C., Jørgensen, N.B., Bojsen-Møller, K.N. et al. (2012) Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. Diabetologia, 55, 1890-1901.
10. Novo Nordisk A/S. (2012) Victoza (liraglutide): Summary of Product Characteristics. Available at: http://www.medicines.org. uk/EMC/medicine/21986/ SPC/Victoza+6+mg+ml+solution+for +injection+in+pre-filled+pen/[Accessed 1st March 2012].
11. Eli Lilly and Company Limited. (2011). Summary of Product Characteristics. Byetta® (exenatide) injection. Available at: http://www.medicines.org.uk/EMC/medicine/19257/SPC/Byetta+5 +micrograms+solution+for+injection%2c+prefilled+pen.++Byetta+ 10+micrograms+solution+for+injection%2c+prefilled+pen./[Accessed 12th March 2012].
12. Eli Lilly and Company Limited. (2011) BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection: Summary of Product Characteristics. Available at: http://www. medicines.org.uk/EMC/medicine/24665/ SPC/BYDUREON+2+mg +powder+and+solvent+for+prolonged-release+suspension+for +injection/. [Accessed 1st March 2012].
13. Knudsen, L.B., Nielsen, P.F., Huusfeldt, P.O. et al. (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry, 43, 1664-1669.
14. Steensgaard, D.B., Thomsen, J.K., Olsen, H.B. et al. (2008) The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes, 57(Suppl. 1), A164.
15. Ahrén, B., Simonsson, E., Larsson, H. et al. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care, 25, 869-875.
16. Merck Sharp & Dohme Corp. (2012). Januvia SmPC. Available at: http://www.medicines.org.uk/EMC/medicine/19609/SPC/JANUVIA+ 25mg%2c+50mg%2c+100mg+film-coated+tablets/[Accessed 1st March 2012].
17. Novartis Pharmaceuticals UK Ltd. (2012) Galvus 50 mg Tablets: Summary of Product Characteristics. Available at: http://www. medicines.org.uk/emc/ medicine/20734 [Accessed 1st March 2012].
18. Bristol-Myers Squibb. (2011) Highlights of prescribing information: Onglyza (saxagliptin) tablets. Available at: http://packageinserts. bms.com/pi/pi-onglyza.pdf. [Accessed 1st March 2012].
19. Boehringer Ingelheim Pharmaceuticals, Inc. (2011). Trajenta SmPC. Available at: http://www.medicines.org.uk/EMC/medicine/25000/SPC/ Trajenta+5+mg+film-coated+tablets/[Accessed 1st March 2012].
20. Buse, J.B., Henry, R.R., Han, J. et al. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care, 27, 2628-2635.
21. DeFronzo, R.A., Ratner, R.E., Han, J. et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care, 28, 1092-1100.
22. Kendall, D.M., Riddle, M.C., Rosenstock, J. et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 28, 1083-1091.
23. Zinman, B., Hoogwerf, B.J., Durán García, S. et al. (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine, 146, 477-485.
24. Heine, R.J., Van Gaal, L.F., Johns, D. et al. (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine, 143, 559-569.
25. Nauck, M.A., Duran, S., Kim, D. et al. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia, 50, 259-267.
26. Drucker, D.J., Buse, J.B., Taylor, K. et al. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. The Lancet, 372, 1240-1250.
27. Bergenstal, R.M., Wysham, C., MacConell, L. et al. (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet, 376, 431-439.
28. Diamant, M., Van Gaal, L., Stranks, S. et al. (2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet, 375, 2234-2243.
29. Russell-Jones, D., Cuddihy, R.M., Hanefeld, M. et al. (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double- blind study. Diabetes Care, 35, 252-258.
30. Blevins, T., Pullman, J., Malloy, J. et al. (2011) DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism, 96, 1301-1310.
31. Buse, J.B., Nauck, M.A., Forst, T. et al. (2011) Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia, 54(Suppl. 1), S38.
32. MacConell, L., Walsh, B., Li, Y. et al. (2011) Exenatide once weekly: sustained improvement in glycemic control and weight loss through 3 years. Diabetes, 60(Suppl. 1), A265.
33. Okerson, T., Yan, P., Stonehouse, A. et al. (2010) Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. American Journal of Hypertension, 23, 334-339.
34. Bunck, M.C., Diamant, M., Cornér, A. et al. (2009) One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care, 32, 762-768.
35. Marre, M., Shaw, J., Brändle, M. et al. (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine, 26, 268-278.
36. Nauck, M., Frid, A., Hermansen, K. et al. (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care, 32, 84-90.
37. Garber, A., Henry, R.R., Ratner, R. et al. (2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 13, 348-356.
38. Zinman, B., Gerich, J., Buse, J.B. et al. (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care, 32, 1224-1230.
39. Russell-Jones, D., Vaag, A., Schmitz, O. et al. (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia, 52, 2046-2055.
40. Buse, J.B., Rosenstock, J., Sesti, G. et al. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet, 374, 39-47.
41. Pratley, R., Nauck, M., Bailey, T. et al. (2011) One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. International Journal of Clinical Practice, 65, 397-407.
42. Gallwitz, B., Vaag, A., Falahati, A. et al. (2010) Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. International Journal of Clinical Practice, 64, 267-276.
43. Fonseca, V., Plutzky, J., Montanya, E. et al. (2010) Liraglutide, a once-daily human GLP-1 analog, lowers systolic blood pressure (SBP) independently of concomitant antihypertensive treatment. Diabetes 59(Suppl. 1), A79 (296-OR).
44. Buse, J.B., Sesti, G., Schmidt, W.E. et al. (2010) Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care, 33, 1300-1303.
45. National Institute for Health and Clinical Excellence. (2010) NICE Technology Appraisal Guidance 203: Liraglutide for the treatment of type 2 diabetes mellitus. Available at: http://www. nice.org.uk/nicemedia/live/13248/ 51259/51259.pdf [Accessed 25 October 2011].
46. Shyangdan, D.S., Royle, P.L., Clar, C. et al. (2010) Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocrine Disorders, 10, 20.
47. DeFronzo, R.A. (2011) Impact of GLP-1 agonists on cardiovascular risk factors in type 2 diabetes mellitus (Advancing Diabetes Care with Incretin-Based Therapies). Medscape Education Diabetes & Endocrinology, Available at: http://www.medscape.org/viewarticle/736759-transcript [Accessed 25 November 2011].
48. Buse, J.B., Garber, A., Rosenstock, J. et al. (2011) Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Journal of Clinical Endocrinology and Metabolism, 96, 1695-1702.
49. Aschner, P., Kipnes, M.S., Lunceford, J.K. et al. (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care, 29, 2632-2637.
50. Charbonnel, B., Karasik, A., Liu, J. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care, 29, 2638-2643.
51. Rosenstock, J., Brazg, R., Andryuk, P.J. et al. (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics, 28, 1556-1568.
52. Pi-Sunyer, F.X., Schweizer, A., Mills, D. et al. (2007) Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Research and Clinical Practice, 76, 132-138.
53. Garber, A.J., Schweizer, A., Baron, M.A. et al. (2007) Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity and Metabolism, 9, 166-174.
54. Garber, A.J., Foley, J.E., Banerji, M.A. et al. (2008) Effects of vildagliptin on glucose control in patients with Type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes, Obesity and Metabolism, 10, 1047-1056.
55. Bolli, G., Dotta, F., Colin, L. et al. (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes, Obesity and Metabolism, 11, 589-595.
56. Bosi, E., Camisasca, R.P., Collober, C. et al. (2007) Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care, 30, 890-895.
57. Rosenstock, J., Aguilar-Salinas, C., Klein, E. et al. (2009) Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Current Medical Research and Opinion, 25, 2401-2411.
58. DeFronzo, R.A., Hissa, M.N., Garber, A.J. et al. (2009) The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled Type 2 diabetes with metformin alone. Diabetes Care, 32, 1649-1655.
59. Chacra, A.R., Tan, G.H., Apanovitch, A. et al. (2009) Saxagliptin added to a submaximal dose of sulfonylurea improves glycemic control compared with uptitration of sulfonylurea in patients with type 2 diabetes: a randomized controlled trial. International Journal of Clinical Practice, 63, 1395-1406.
60. Hollander, P., Li, J., Allen, E. et al. (2009) Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. Journal of Clinical Endocrinology and Metabolism, 94, 4810 -4819.
61. Taskinen, M.R., Rosenstock, J., Tamminen, I. et al. (2011) Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, 13, 65-74.
62. Gomis, R., Espadero, R.M., Jones, R. et al. (2011) Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes, Obesity and Metabolism, 13, 653-661.
63. Del Prato, S., Barnett, A.H., Huisman, H. et al. (2011) Effect of linagliptin monotherapy on glycaemic control and markers of bcell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes, Obesity and Metabolism, 13, 258-267.
64. Horton, E.S., Silberman, C., Davis, K.L. et al. (2010) Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care, 33, 1759-1765.
65. Bethel, M.A., Green, J., Califf, R.M. et al. (2009) Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, 58(Suppl. 1), A639.
66. Esposito, K., Cozzolino, D., Bellastella, G. et al. (2011) Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 13, 594-603.
67. Willemen, M.J., Mantel-Teeuwisse, A.K., Straus, S.M. et al. (2011) Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. Diabetes Care, 34, 369-374.
68. Elashoff, M., Matveyenko, A.V., Gier, B. et al. (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1- based therapies. Gastroenterology, 141, 150-156.
69. Drucker, D.J., Sherman, S.I., Bergenstal, R.M. et al. (2011) The safety of incretin-based therapies-review of the scientific evidence. Journal of Clinical Endocrinology and Metabolism, 96, 2027-2031.
70. European Association for the Study of Diabetes. (2011). EASD commentary on the publication by Elashoff et al., published online in Gastroenterology, February 2011: Increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1-based therapy. Available at: http://87.234.226.93/ easd- intranet/easdwebfiles/statements/Elashoff-Commentary.pdf. [Accessed 11 January 2011].
71. National Institute for Health and Clinical Excellence. (2009) NICE Clinical Guideline 87: Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. Available at: http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf [Accessed 25 October 2011].
72. Rodbard, H.W. & Jellinger, P.S. (2010) The American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) algorithm for managing glycaemia in patients with type 2 diabetes mellitus: comparison with the ADA/EASD algorithm. Diabetologia, 53, 2458-2460.
73. National Institute for Health and Clinical Excellence. (2012) Technology Appraisal 248 (TA248): Diabetes (type 2) - exenatide (prolonged release). Available at: http://www.nice.org.uk/guidance/TA248 [Accessed 6 June 2012].
74. Buse, J.B., Bergenstal, R.M., Glass, L.C. et al. (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Annals of Internal Medicine, 154, 103-112.
75. Bain, S.C., De Vries, J.H., Seufert, J., et al. (2011) Adding insulin detemir (IDet) to liraglutide and metformin improves glycaemic control with sustained weight reduction and low hypoglycaemia rate: 52 week results. Diabetologia, 54(Suppl. 1), S37.
76. Novo Nordisk Limited. (2012) Levemir Cartridge 100 U/ml - Penfill, Levemir Pre-filled Pen 100 U/ml - FlexPen and InnoLet: Summary of Product Characteristics. Available at: http://www. medicines.org.uk/EMC/medicine/14584/ SPC/Levemir++Cartridge +100+U+ml+-+Penfill%2c++Levemir+Pre-filled+Pen+100+U +ml+-+FlexPen+and+InnoLet/. [Accessed 7 March 2012].
77. Gallwitz, B. (2011) Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opinion on Investigational Drugs, 20, 723-732.
78. Neumiller, J.J. (2011) Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clinical Therapeutics, 33, 528-576.
79. Christensen, M., Knop, F.K., Vilsbøll, T. et al. (2011) Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 20, 549-557.
80. Fonseca, V.A., Alvarado-Ruiz, R., Raccah, D. et al. (2012) Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebocontrolled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care, 35, 1225-1231.
81. Jimenez-Solem, E., Rasmussen, M.H., Christensen, M. et al. (2010) Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Current Opinion in Molecular Therapeutics, 12, 790-797.
82. Luskey, K., Rosenstock, J., Alessi, T. et al. (2011) Long-term, injection-free treatment with ITCA 650, a continuous subcutaneous delivery of exenatide via DUROS® device, leads to stable glycaemic and weight control for 48 weeks in metformin-treated type 2 diabetes. Diabetologia, 54(Suppl. 1), S39.
83. MacConell, L., Malloy, J., Huang, W. et al. (2011) Safety and efficacy of once monthly exenatide administration over 20 weeks in patients with type 2 diabetes. Diabetologia, 54(Suppl. 1), S38.
84. Choi, I.Y., Jung, S.Y., Lim, C.G. et al. (2011) LAPS-exendin-4 analog, a novel long-acting GLP-1R agonist for weekly or monthly dosing in T2 DM patients. Diabetes, 60(Suppl. 1), A612.
85. Fosgerau, K., Skovgaard, M., Larsen, S.A. et al. (2011) Combination of long-acting insulin with the dual GluGLP-1 agonist ZP2929 causes improved glycemic control without body weight gain in db/db mice. Diabetes, 60(Suppl. 1), A418.
86. Fosgerau, K., Tolborg, J.L., Østerlund, T. et al. (2011) The new GLP-1-gastrin dual agonist ZP3022 prevents diabetes in db/db mice. Diabetes, 60(Suppl. 1), A4540.
87. Rosenstock, J., Lewin, A.J., Norwood, P. et al. (2011) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes. Diabetic Medicine, 28, 464-469.
88. Suen, C.S. & Burn, P. (2012) The potential of incretin-based therapies in type 1 diabetes. Drug Discovery Today, 17, 89-95.
89. Kielgast, U., Holst, J.J. & Madsbad, S. (2011) Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-cell function. Diabetes, 60, 1599-1607.
90. Varanasi, A., Bellini, N., Rawal, D. et al. (2011) Liraglutide as an additional treatment in type 1 diabetes. European Journal of Endocrinology, 165, 77-84.
91. Paisley, A.N., Savage, M.W. & Wiles, P.G. (2009) Stabilizing effect of exenatide in a patient with C-peptide negative diabetes mellitus. Diabetic Medicine, 26, 935-938.
92. Kutoh, E. (2011) Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. Journal of Medical Case Reports, 5, 117-121.
93. NICE Pathway: Blood-glucose-lowering therapy for type 2 diabetes. (2012). Available at: http://pathways.nice.org.uk/pathways/diabetes/managing-type-2- diabetes#path=view%3A/pathways/diabetes/blood-glucose-lowering-therapy-for-type- 2-diabetes. xml&content=close.